These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Editorial comment on: Intraprostatic and bladder-neck botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study. Michel M Eur Urol; 2008 Mar; 53(3):626-7. PubMed ID: 17950523 [No Abstract] [Full Text] [Related]
27. Preclinical assessment of potential interactions between botulinum toxin and neuromodulation for bladder micturition reflex. Su X; Nickles A; Nelson DE BMC Urol; 2015 Jun; 15():50. PubMed ID: 26055982 [TBL] [Abstract][Full Text] [Related]
28. Editorial comment on: Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study. Pickard R Eur Urol; 2008 Mar; 53(3):626. PubMed ID: 17950524 [No Abstract] [Full Text] [Related]
32. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Antunes AA; Srougi M; Coelho RF; de Campos Freire G Nat Clin Pract Urol; 2007 Mar; 4(3):155-60. PubMed ID: 17347660 [TBL] [Abstract][Full Text] [Related]
33. [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A]. Amend B; Castro-Diaz D; Chartier-Kastler E; De Ridder D; Everaert K; Spinelli M; van Kereebroeck P; Sievert KD Urologe A; 2010 Feb; 49(2):245-52. PubMed ID: 19859688 [TBL] [Abstract][Full Text] [Related]
34. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study. Grosse J; Kramer G; Jakse G BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462 [TBL] [Abstract][Full Text] [Related]
35. [Guidelines for the treatment of urinary incontinence in women with refractory idiopathic vesical hyperactivity using sacral neuromodulation]. Cardot V; Berlizot P; Le Normand L; Prog Urol; 2010 Feb; 20 Suppl 2():S161-9. PubMed ID: 20403569 [TBL] [Abstract][Full Text] [Related]
36. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Fowler CJ Eur Urol; 2009 Mar; 55(3):712. PubMed ID: 18814958 [No Abstract] [Full Text] [Related]
37. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Schurch B Eur Urol; 2009 Mar; 55(3):711-2. PubMed ID: 18814956 [No Abstract] [Full Text] [Related]
38. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Apostolidis A; Jacques TS; Freeman A; Kalsi V; Popat R; Gonzales G; Datta SN; Ghazi-Noori S; Elneil S; Dasgupta P; Fowler CJ Eur Urol; 2008 Jun; 53(6):1245-53. PubMed ID: 18343564 [TBL] [Abstract][Full Text] [Related]
39. [Input from a specialized nurse consultation in the management of detrusor overactivity treated with intradetrusor injections of botulinum toxin in urology department. Pilot study]. Le Gal S; Safsaf A; Galliot I; Catovic B; Grise P Prog Urol; 2010 Sep; 20(8):584-9. PubMed ID: 20832036 [TBL] [Abstract][Full Text] [Related]
40. Overactive bladder in children. Part 2: Management. Franco I J Urol; 2007 Sep; 178(3 Pt 1):769-74; discussion 774. PubMed ID: 17631332 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]